Evidence map›Paper›PMID 38138504›Full record

ArticleMolecules (Basel, Switzerland)2023

Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action.

Svetlana Miroshnichenko, Mariya Pykhtina, Anastasiia Kotliarova, Alexander Chepurnov, Anatoly Beklemishev

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Svetlana MiroshnichenkoFederal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
Mariya PykhtinaFederal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
Anastasiia KotliarovaN.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.ORCID 0000-0003-1071-9724
Alexander ChepurnovFederal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
Anatoly BeklemishevFederal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
Federal Research Center of Fundamental and Translational Medicine · RUNovosibirsk Institute of Organic Chemistry · RU

Funding

This research was supported by the Federal budget for the Program Fundamental Research of state academies of sciences . project No. 0535-2019-0030
6 · The paper itself

Abstract

Recombinant human interferon alpha-2b (rIFN) is widely used in antiviral and anticancer immunotherapy. However, the high efficiency of interferon therapy is accompanied by a number of side effects; this problem requires the design of a new class of interferon molecules with reduced cytotoxicity. In this work, IFN was modified via genetic engineering methods by merging it with the blood plasma protein apolipoprotein A-I in order to reduce acute toxicity and improve the pharmacokinetics of IFN. The chimeric protein was obtained via biosynthesis in the yeast

Indexed as

Apolipoproteins AInterferon-alphaAnimalsApolipoprotein A-IChlorocebus aethiopsHumansInterferon alpha-2MiceRecombinant Fusion ProteinsRecombinant ProteinsVero CellsApolipoprotein A-IApolipoproteins AInterferon-alphaInterferon alpha-2Recombinant Fusion ProteinsRecombinant Proteinsantiviral activityapolipoprotein A-I (ApoA-I)apoptosiscytotoxicityfusion proteinPichia pastorisprolonged half-lifeSARS-CoV-2Tween 20yeast-derived IFNα2b (ryIFN)

Identifiers

PMID38138504
PMCPMC10745500
OpenAlexW4389488356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.